Feds making ‘assessment of demand’ from provinces for Johnson & Johnson vaccine supply

Procurement Minister Anita Anand says the federal government is conducting an “assessment of demand” for Johnson & Johnson’s COVID-19 vaccine supply with provinces and territories.

“Decisions are still being made regarding the J&J vaccine deliveries, but by all means, that contract is still in place and still able to yield vaccines for Canadians if the demand is there,” Anand said Tuesday.

The single-dose vaccine was initially lauded as a turning point for countries such as Canada looking to speed up vaccination efforts.

But after a manufacturing mishap at a U.S. manufacturing plant in Baltimore, Health Canada said it wouldn’t release more than 300,000 doses of the vaccine over quality concerns and will continue to hold them back until an American investigation into the facility is complete.

Canada has signed an agreement for 10 million doses of the J&J shot. Joelle Paquette, the director-general responsible for vaccine procurement at Public Services and Procurement Canada, said Friday that the country could expect to receive a shipment of the vaccines by the end of June, but whether any shipments have been delivered remains unclear.

Global News reached out to Anand’s office to confirm vaccine shipments but did not immediately hear back.

2:58Johnson & Johnson COVID-19 vaccine recommended for adults 30+ in Canada: NACI

Brig. Gen. Krista Brodie, the military commander in charge of the country’s national vaccine delivery logistics, said that “at this point in time, we are not receiving a strong demand signal at all from the provinces” for J&J shots.

“We are focused on the mRNA vaccines, which are those that are really in demand by the provinces in order to accelerate those second dose strategies and to really get as many first doses as we can as soon as possible.”

J&J’s one-shot vaccine differs from Pfizer-BioNtech and Moderna’s mRNA vaccines, which require two doses. It is an adenovirus-based vaccine that showed an overall efficacy of 66 per cent in preventing moderate to severe COVID-19 in clinical trials.

It was recommended for adults aged 30 years and older in May.

By the end of this week, Canada is expected to have received deliveries of 50 million doses of all vaccines for use by Health Canada — the vast majority of which being shots from Pfizer and Moderna.

More to come. 

–With files from Global News’ Saba Aziz and the Canadian Press

View link »